Latest news about Gujarat Kidney and Super Speciality
Gujarat Kidney and Super Speciality
171.51
+3.21(+1.91%)
Company Performance:
View Company Insights1D+1.91%
1M+34.71%
6M+55.35%
1Y0.00%
5Y0.00%
More news about Gujarat Kidney and Super Speciality
14Aug 26
Gujarat Kidney Q1 Results: Net profit rises to 52M rupees, revenue more than doubles YoY
Gujarat Kidney and Super Speciality posted a consolidated net profit of 52M rupees in Q1, compared to 48M rupees in the year-ago period. Revenue surged to 343M rupees from 153M rupees on a year-on-year basis, reflecting significant topline expansion. Both metrics improved year-on-year, with revenue more than doubling while net profit recorded modest growth.
23Jul 26
Gujarat Kidney seeks vote to reallocate IPO proceeds
Gujarat Kidney and Superspeciality Limited has called for a postal ballot to approve the reallocation of ₹25.14 crore in IPO proceeds. The funds, initially meant for a new hospital in Bharuch, will be redirected towards expanding existing infrastructure (₹17.92 crore) and acquiring a 51% stake in Blue Tree Clinics LLC in Dubai (₹7.22 crore). Shareholders can cast their votes via remote e-voting until August 22, 2026.
21Jul 26
Gujarat Kidney appoints Paresh Dhoti as Non-Executive Non-Independent Director
Gujarat Kidney and Super Speciality Ltd appointed Mr Paresh Dhoti as an Additional Non-Executive Non-Independent Director on July 9, 2026, due to a technical issue with his independent director registration. The company will consider him for the Independent Director role in a future board meeting.
13Jul 26
Gujarat Kidney acquires 51% stake in Blue Tree Clinics LLC, UAE
Gujarat Kidney and Super Speciality Limited approved acquiring a 51% stake in Blue Tree Clinics LLC, UAE, for ₹19,83,64,500. The Board also appointed Mr. Paresh Dhoti as an Additional Independent Director and approved a postal ballot for IPO object variation.
11Jul 26
Gujarat Kidney corrects signing date error in Q1FY26 results
Gujarat Kidney and Super Speciality Limited corrected a typographical error in the signing date of its Q1FY26 financial results, confirming the actual date as 28-May-2025. The company clarified that the error does not affect the financial figures or disclosures. For the year ended 31 March 2026, the company reported a total income of ₹4,059.47 lacs and a profit after tax of ₹990.14 lacs.
07Jul 26
Gujarat Kidney approves variation in IPO proceeds utilisation
Gujarat Kidney and Super Speciality Limited received shareholder approval to vary the objects and terms of utilisation of its IPO proceeds via a postal ballot. The special resolution passed with 99.9995% of votes in favour, with 56,894,699 votes supporting the proposal and 286 against.
05Jun 26
Gujarat Kidney seeks nod to vary IPO proceeds utilization
Gujarat Kidney And Superspeciality Limited has initiated a remote e-voting process from June 05 to July 04, 2026, to seek shareholder approval for varying the utilization of its IPO proceeds. The company proposes to reallocate Rs 37.76 crore, utilizing Rs 6.12 crore for healthcare expansion in its subsidiary and parent company, and transferring Rs 19.02 crore to fund inorganic growth and general corporate purposes. The decision follows a review of a previous proposal to incorporate a new subsidiary, aiming to avoid duplication of resources. The results of the postal ballot will be announced on or before July 07, 2026.
29May 26
Gujarat Kidney FY26 profit rises, appoints auditors
Gujarat Kidney And Superspeciality Limited reported its audited standalone and consolidated financial results for the year ended March 31, 2026, showing a rise in standalone profit after tax to ₹990.14 lacs and consolidated profit after tax to ₹1,681.18 lacs. The board appointed internal and secretarial auditors and deferred the CEO appointment while seeking shareholder approval for a variation in its IPO objects via postal ballot.
28May 26
Gujarat Kidney promoters declare no encumbrance in FY26
Gujarat Kidney and Super Speciality Limited confirmed via a regulatory filing that its promoters did not encumber any shares during FY26. The disclosure, signed by promoter Pragnesh Bharpoda, was submitted to BSE and NSE on April 7, 2026, under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
15May 26
Gujarat Kidney and Super Speciality to Deploy 100 AI-Powered Haemodialysis Machines Across Gujarat Network
Gujarat Kidney and Super Speciality Limited has announced the procurement of 100 AI-enabled haemodialysis machines, with Phase-1 deployment of 8 units at its Gujarat Multi Speciality Hospital, Godhra facility within 10 days of the announcement dated 14 May 2026. The AI-powered machines offer real-time decision support, early complication detection, and personalised treatment parameters, with the remaining units to be progressively deployed across GKSL's dialysis centre network across Gujarat.
25Apr 26
Gujarat Kidney and Super Speciality Limited Postal Ballot Results: All Resolutions Approved
Gujarat Kidney and Super Speciality Limited shareholders approved all three resolutions through postal ballot on 25-04-2026, including healthcare expansion funding (100% approval), voluntary revision of financial statements under Section 131 (99.9998% approval), and appointment of Mr. Dharmendra Bhaliya as Secretarial Auditor for FY 2025-26 (99.9994% approval). The e-voting process conducted from 27th March to 25th April 2026 achieved 72.1003% participation with 56,846,254 votes cast out of 78,843,250 total shares.
22Apr 26
Gujarat Kidney Pays Rs 20,000 Fines to BSE and NSE for Board Meeting Delay
Gujarat Kidney and Super Speciality Limited has paid Rs 20,000 in total fines to BSE and NSE for failing to provide prior intimation about board meetings under SEBI Regulation 29(2)/29(3). The penalties of Rs 10,000 each were imposed on April 15, 2026, and paid via NEFT on April 16, 2026. The company confirmed no impact on financial, operational, or other activities.
07Apr 26
Gujarat Kidney and Super Speciality Limited Submits SEBI Compliance Certificate for Q4FY26
Gujarat Kidney and Super Speciality Limited has submitted its mandatory SEBI compliance certificate for Q4FY26, confirming all shares are in electronic form. The certificate, issued by registrar MUFG Intime India Private Limited on April 6, 2026, was submitted to BSE and NSE on April 7, 2026, fulfilling Regulation 74(5) requirements for the quarter ended March 31, 2026.
26Mar 26
Gujarat Kidney Completes Postal Ballot Notice Dispatch for IPO Fund Reallocation
Gujarat Kidney and Super Speciality Limited has completed the dispatch of its postal ballot notice to shareholders, announcing through newspaper publications on March 26, 2026. The company seeks approval for reallocating ₹3,692.50 lakhs of unutilized IPO funds from women's hospital and robotics equipment to developing a multi-specialty hospital in Bharuch and dialysis services collaboration. The e-voting process runs from March 27 to April 25, 2026, with results expected within two working days.
23Mar 26
Gujarat Kidney and Super Speciality Limited Acquires Parekhs Hospital for ₹77 Crore
Gujarat Kidney and Super Speciality Limited completed acquisition of Parekhs Hospital Private Limited as wholly owned subsidiary on March 22, 2026, for ₹77 crore cash consideration. The target company, incorporated in 2006, operates in medical and healthcare services with revenues of ₹25.67 crore in FY25. The strategic acquisition aims to strengthen presence in healthcare sector and diversify business portfolio.
21Mar 26
Gujarat Kidney Pays ₹6.61 Lakh Penalty to NSE and BSE for Regulatory Non-Compliance
Gujarat Kidney and Super Speciality Limited has completed payment of regulatory penalties totaling ₹6,60,800 to NSE and BSE for failing to submit quarterly financial results within prescribed timelines. The company paid ₹3,30,400 to each exchange via RTGS on March 20, 2026, following penalty notices received on March 17, 2026, and has formally communicated the settlement to both exchanges.
19Mar 26
Gujarat Kidney Appoints Auditors and Approves Postal Ballot with Q2 FY25 Results
Gujarat Kidney And Superspeciality Limited conducted a board meeting on March 19, 2026, appointing Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY 2025-26. The board also approved postal ballot notice and ratified Q2 FY25 financial results, which showed consolidated revenue growth of 37.40% to ₹1,292.88 lacs despite a decline in net profit.
13Mar 26
Gujarat Kidney And Super Speciality Limited Reports Mixed Q2FY26 Results with Revenue Decline
Gujarat Kidney And Super Speciality Limited reported Q2FY26 standalone revenue of ₹964.26 lacs, up 2.47% YoY, but net profit declined 22.17% to ₹230.12 lacs due to rising expenses. Half-year performance showed stronger growth with revenue increasing 12.97% to ₹2,109.25 lacs and net profit rising 10.12% to ₹620.10 lacs. Consolidated results demonstrated significant revenue growth of 37.40% to ₹1,292.88 lacs, reflecting successful expansion through subsidiaries, though profitability remained under pressure with EPS declining across both standalone and consolidated operations.
Industry Peers
Apollo Hospitals
Max Healthcare Institute
Fortis Healthcare
Aster DM Quality Care
Narayana Hrudayalaya
Global Health
Krishna Institute of Medical Sciences
Dr. Agarwal's Health Care
Rainbow Childrens Medicare
Park Medi World
8,692.00
(-0.31%)
994.90
(+0.09%)
917.50
(+0.27%)
787.00
(+3.57%)
1,882.20
(-2.11%)
1,417.30
(-1.91%)
767.85
(+1.88%)
511.45
(-0.54%)
1,440.80
(+0.54%)
286.70
(+3.60%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
